Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A sub-analysis of the PROTECT trial.

Kenya KusunoseTakumi ImaiAtsushi TanakaMasaru DoiYuji KoideKazuo FukumotoToshiaki KadokamiMitsuru OhishiHiroki TeragawaNobuyuki OhteHirotsugu YamadaMasataka SataKoichi Nodenull null

Published in: Journal of cardiology (2024)

Ipragliflozin generally improved LV diastolic function in patients with type 2 diabetes, the extent of this improvement might appear to vary with LV systolic function.

Keyphrases

left ventricular
blood pressure
heart failure
acute myocardial infarction
hypertrophic cardiomyopathy
cardiac resynchronization therapy
clinical trial
mitral valve
left atrial
aortic stenosis
acute coronary syndrome
phase iii
transcatheter aortic valve replacement
atrial fibrillation